Published in Int J Mol Sci on June 19, 2015
An Anti-Parkinson's Disease Drug via Targeting Adenosine A2A Receptor Enhances Amyloid-β Generation and γ-Secretase Activity. PLoS One (2016) 1.40
Neuro-psychopharmacological perspective of Orphan receptors of Rhodopsin (class A) family of G protein-coupled receptors. Psychopharmacology (Berl) (2017) 0.75
How many drug targets are there? Nat Rev Drug Discov (2006) 14.22
The functional anatomy of basal ganglia disorders. Trends Neurosci (1989) 12.28
D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science (1990) 8.07
Lateral habenula as a source of negative reward signals in dopamine neurons. Nature (2007) 6.32
Episodic memory, amnesia, and the hippocampal-anterior thalamic axis. Behav Brain Sci (1999) 5.12
D1 and D2 dopamine-receptor modulation of striatal glutamatergic signaling in striatal medium spiny neurons. Trends Neurosci (2007) 4.93
The repertoire of G-protein-coupled receptors in fully sequenced genomes. Mol Pharmacol (2005) 4.07
The neurobiology of slow synaptic transmission. Science (2001) 3.97
Circuits and circuit disorders of the basal ganglia. Arch Neurol (2007) 3.97
DARPP-32: an integrator of neurotransmission. Annu Rev Pharmacol Toxicol (2004) 3.84
Striatal interneurones: chemical, physiological and morphological characterization. Trends Neurosci (1995) 3.65
The G protein-coupled receptor repertoires of human and mouse. Proc Natl Acad Sci U S A (2003) 3.24
Synaptic organisation of the basal ganglia. J Anat (2000) 3.12
Functional diversity and specificity of neostriatal interneurons. Curr Opin Neurobiol (2004) 2.94
Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl) (1996) 2.91
Anatomical profiling of G protein-coupled receptor expression. Cell (2008) 2.88
Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther (1989) 2.78
Antipsychotics in adults with schizophrenia: comparative effectiveness of first-generation versus second-generation medications: a systematic review and meta-analysis. Ann Intern Med (2012) 2.52
Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET. Nature (1997) 2.46
Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia. Trends Neurosci (1997) 2.23
Targeting adenosine A2A receptors in Parkinson's disease. Trends Neurosci (2006) 2.14
Lipid G protein-coupled receptor ligand identification using beta-arrestin PathHunter assay. J Biol Chem (2009) 1.91
Adenosine A2A receptors and basal ganglia physiology. Prog Neurobiol (2007) 1.90
Distribution of striatonigral and striatopallidal peptidergic neurons in both patch and matrix compartments: an in situ hybridization histochemistry and fluorescent retrograde tracing study. Brain Res (1988) 1.78
Progress towards validating the NMDA receptor hypofunction hypothesis of schizophrenia. Curr Top Med Chem (2006) 1.77
Striatal restricted adenosine A2 receptor (RDC8) is expressed by enkephalin but not by substance P neurons: an in situ hybridization histochemistry study. J Neurochem (1991) 1.69
Caffeine and schizophrenia. J Clin Psychiatry (1978) 1.66
Cell type-specific regulation of DARPP-32 phosphorylation by psychostimulant and antipsychotic drugs. Nat Neurosci (2008) 1.63
Synaptic transmission: a bidirectional and self-modifiable form of cell-cell communication. Cell (1993) 1.45
Region-specific transcriptional changes following the three antidepressant treatments electro convulsive therapy, sleep deprivation and fluoxetine. Mol Psychiatry (2006) 1.42
Levodopa-induced dyskinesias and dopamine-dependent stereotypies: a new hypothesis. Trends Neurosci (2000) 1.39
Do orphan G-protein-coupled receptors have ligand-independent functions? New insights from receptor heterodimers. EMBO Rep (2006) 1.31
Genetic control of instrumental conditioning by striatopallidal neuron-specific S1P receptor Gpr6. Nat Neurosci (2007) 1.30
Potentiation of NMDA receptor currents by dopamine D1 receptors in prefrontal cortex. Proc Natl Acad Sci U S A (2004) 1.29
Dopamine D1 receptors mediate CREB phosphorylation via phosphorylation of the NMDA receptor at Ser897-NR1. J Neurochem (2003) 1.29
A critical role of the adenosine A2A receptor in extrastriatal neurons in modulating psychomotor activity as revealed by opposite phenotypes of striatum and forebrain A2A receptor knock-outs. J Neurosci (2008) 1.27
Lack of GPR88 enhances medium spiny neuron activity and alters motor- and cue-dependent behaviors. Nat Neurosci (2012) 1.25
Adenosine A2 receptor-mediated excitatory actions on the nervous system. Prog Neurobiol (1996) 1.24
How much of reinforcement learning is working memory, not reinforcement learning? A behavioral, computational, and neurogenetic analysis. Eur J Neurosci (2012) 1.23
Sphingosine 1-phosphate is a ligand of the human gpr3, gpr6 and gpr12 family of constitutively active G protein-coupled receptors. Cell Signal (2002) 1.22
Drug-induced potentiation of prepulse inhibition of acoustic startle reflex in mice: a model for detecting antipsychotic activity? Psychopharmacology (Berl) (2001) 1.20
The orphan GPCR, GPR88, modulates function of the striatal dopamine system: a possible therapeutic target for psychiatric disorders? Mol Cell Neurosci (2009) 1.16
Effects of the acute administration of caffeine in patients with schizophrenia. Biol Psychiatry (1990) 1.13
Diagnosis and classification of schizophrenia. Schizophr Bull (1993) 1.10
Aripiprazole, a novel antipsychotic agent: dopamine D2 receptor partial agonist. J Med Invest (2005) 1.10
Neural expression of G protein-coupled receptors GPR3, GPR6, and GPR12 up-regulates cyclic AMP levels and promotes neurite outgrowth. J Biol Chem (2007) 1.09
Adenosine A2A agonists: a potential new type of atypical antipsychotic. Neuropsychopharmacology (1997) 1.04
Involvement of adenosine A1 and A2A receptors in the adenosinergic modulation of the discriminative-stimulus effects of cocaine and methamphetamine in rats. J Pharmacol Exp Ther (2003) 1.02
Agonist-trafficking and hallucinogens. Curr Med Chem (2009) 1.00
Aripiprazole acts as a selective dopamine D2 receptor partial agonist. Expert Opin Investig Drugs (2007) 0.95
Local control of striatal dopamine release. Front Behav Neurosci (2014) 0.94
Inhibition of NMDA receptor-mediated currents in isolated rat hippocampal neurones by adenosine A1 receptor activation. Neuroreport (1995) 0.94
Modulation of GABAergic transmission in the striatopallidal system by adenosine A2A receptors: a potential mechanism for the antiparkinsonian effects of A2A antagonists. Neurology (2003) 0.93
Two new adenosine receptor antagonists for the treatment of Parkinson's disease: istradefylline versus tozadenant. Expert Opin Pharmacother (2014) 0.90
Unraveling the differential functions and regulation of striatal neuron sub-populations in motor control, reward, and motivational processes. Front Behav Neurosci (2011) 0.90
Tuning and fine-tuning of synapses with adenosine. Curr Neuropharmacol (2009) 0.89
Association study in three different populations between the GPR88 gene and major psychoses. Mol Genet Genomic Med (2013) 0.89
Synthesis, pharmacological characterization, and structure-activity relationship studies of small molecular agonists for the orphan GPR88 receptor. ACS Chem Neurosci (2014) 0.88
Schizophrenia drug discovery and development in an evolving era: are new drug targets fulfilling expectations? J Psychopharmacol (2015) 0.85
A striatal-enriched intronic GPCR modulates huntingtin levels and toxicity. Elife (2015) 0.83
Adenosine A2A receptors inhibit the N-methyl-D-aspartate component of excitatory synaptic currents in rat striatal neurons. Eur J Pharmacol (2002) 0.82
Local inactivation of Gpr88 in the nucleus accumbens attenuates behavioral deficits elicited by the neonatal administration of phencyclidine in rats. Mol Psychiatry (2014) 0.82
Temporal and spatial transcriptional fingerprints by antipsychotic or propsychotic drugs in mouse brain. PLoS One (2015) 0.81
The adenosine A1 receptor agonist N6-cyclopentyladenosine blocks the disruptive effect of phencyclidine on prepulse inhibition of the acoustic startle response in the rat. Eur J Pharmacol (1999) 0.80
Association studies of the adenosine A2a receptor (1976T > C) genetic polymorphism in Parkinson's disease and schizophrenia. J Neural Transm (Vienna) (2005) 0.80
Mapping of the human adenosine A2a receptor gene: relationship to potential schizophrenia loci on chromosome 22q and exclusion from the CATCH 22 region. Hum Genet (1997) 0.79
Adenosine A1 and A2 receptor agonists significantly prevent the electroencephalographic effects induced by MK-801 in rats. Eur J Pharmacol (1997) 0.78
Anatomical transcriptome of G protein-coupled receptors leads to the identification of a novel therapeutic candidate GPR52 for psychiatric disorders. PLoS One (2014) 0.78
How do the atypical antipsychotics work? J Psychiatry Neurosci (2001) 0.78
Discovery of the first potent and orally available agonist of the orphan G-protein-coupled receptor 52. J Med Chem (2014) 0.76
G-protein coupled receptor 6 deficiency alters striatal dopamine and cAMP concentrations and reduces dyskinesia in a mouse model of Parkinson's disease. Exp Neurol (2014) 0.76